iTeos Therapeutics, Inc.
ITOS
$10.13
$0.000.00%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | 0.00 | -- | 35.00M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | 0.00 | -- | 35.00M |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | 0.00 | -- | 35.00M |
SG&A Expenses | 10.18M | 10.98M | 11.81M | 12.11M | 12.46M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 66.70M | 39.53M | 48.48M | 48.63M | 48.27M |
Operating Income | -66.70M | -39.53M | -48.48M | -48.63M | -13.27M |
Income Before Tax | -77.06M | -33.51M | -36.36M | -43.12M | -4.87M |
Income Tax Expenses | 1.67M | 1.10M | 7.36M | 2.24M | 2.26M |
Earnings from Continuing Operations | -78.73M | -34.61M | -43.71M | -45.36M | -7.13M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -78.73M | -34.61M | -43.71M | -45.36M | -7.13M |
EBIT | -66.70M | -39.53M | -48.48M | -48.63M | -13.27M |
EBITDA | -66.36M | -39.20M | -48.16M | -48.32M | -12.96M |
EPS Basic | -1.81 | -0.80 | -1.01 | -1.05 | -0.18 |
Normalized Basic EPS | -0.87 | -0.48 | -0.53 | -0.62 | -0.08 |
EPS Diluted | -1.81 | -0.80 | -1.01 | -1.05 | -0.18 |
Normalized Diluted EPS | -0.87 | -0.48 | -0.53 | -0.62 | -0.08 |
Average Basic Shares Outstanding | 43.56M | 43.24M | 43.18M | 43.14M | 39.70M |
Average Diluted Shares Outstanding | 43.56M | 43.24M | 43.18M | 43.14M | 39.70M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |